{"entity":{"id":"nct06713369","kind":"trial","name":"AZD5305 hADME in Patients With Advanced Solid Malignancies","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06713369 as recruiting, last updated 2026-06-24. Enrolment is 8 planned participants, an estimate. Interventions: Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose). Primary measures include Absolute bioavailability (F) of Saruparib; Total radioactivity recovery in urine and faeces. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06713369","url":"https://clinicaltrials.gov/study/NCT06713369"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06713369","phase":"1","setting":"A Phase I, Open-label Study to Assess the Absolute Bioavailability of Saruparib (AZD5305) and Absorption, Distribution, Metabolism, and Excretion (ADME) of [14C]-Saruparib ([14C]-AZD5305) in Patients With Advanced Solid Malignancies","sponsor":"AstraZeneca","started":"2025-04-02","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06713369/","neighbours":{"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"}]}}